A 28-year-old woman from Delhi presents with a 3-month history of arthralgia affecting her hands, wrists, and knees, along with a malar rash that worsens in sunlight. She reports fatigue, low-grade fever, and recent hair loss. On examination, she has a butterfly rash over the cheeks and nasal bridge, oral ulcers, and non-erosive arthritis. Laboratory investigations show: ANA positive (1:640, homogeneous pattern), anti-dsDNA antibodies positive (180 IU/mL; normal <70), anti-Smith antibodies positive, complement C3 level 45 mg/dL (normal 80–160), and urinalysis shows mild proteinuria (0.8 g/24 h) with occasional RBC casts. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Diagnosis & Severity Assessment **Key Point:** This patient meets ACR/EULAR 2019 SLE classification criteria with: - Malar rash (photosensitive) - Oral ulcers - Non-erosive arthritis - Positive ANA, anti-dsDNA, anti-Smith - Low complement C3 - Mild renal involvement (proteinuria + RBC casts) The presence of anti-dsDNA, low complement, and RBC casts indicates **active lupus nephritis (WHO Class I–II or early Class III)**, despite modest proteinuria. ## Management Rationale ### Hydroxychloroquine **High-Yield:** Hydroxychloroquine 200–400 mg daily is the **foundation therapy** for all SLE patients, regardless of organ involvement. It reduces disease flares, improves survival, and is safe in pregnancy [cite:Harrison 21e Ch 319]. ### Corticosteroid Dosing **Clinical Pearl:** At this stage of renal disease (proteinuria <1 g/day, no significant renal dysfunction), **low-dose prednisolone (0.5 mg/kg/day)** is appropriate. Pulse methylprednisolone is reserved for severe proliferative nephritis (Class III–IV) with heavy proteinuria or rapidly declining GFR. ### Renal Monitoring **Key Point:** A 24-hour urine protein collection is essential to: - Quantify baseline proteinuria (predicts progression) - Establish a benchmark for response assessment - Guide escalation to immunosuppression if proteinuria worsens RBC casts + low complement + anti-dsDNA = **active glomerulonephritis**. Renal biopsy is NOT immediately indicated; reserve it for: - Atypical presentations - Failure to respond to standard therapy - Need to distinguish lupus from superimposed ANCA-associated vasculitis ### Why Not Immediate Pulse Therapy or Renal Biopsy? Mild proteinuria (<1 g/day) and stable renal function do not warrant aggressive induction therapy. A trial of hydroxychloroquine + low-dose prednisolone with close monitoring is the standard-of-care first step [cite:Kidney Disease: Improving Global Outcomes (KDIGO) 2021 SLE Nephritis Guideline]. ```mermaid flowchart TD A["SLE with RBC casts + proteinuria 0.8 g/24h"]:::outcome --> B{"Proteinuria > 1 g/day OR rapid GFR decline?"}:::decision B -->|No| C["Start HCQ 200 mg daily"]:::action B -->|No| D["Prednisolone 0.5 mg/kg/day"]:::action B -->|No| E["Obtain 24-h urine protein"]:::action B -->|No| F["Monitor monthly: renal function, proteinuria, complement"]:::action B -->|Yes| G["Pulse methylprednisolone + immune suppression"]:::urgent F --> H{"Proteinuria worsens OR GFR declines?"}:::decision H -->|Yes| I["Escalate: MMF or CYC"]:::action H -->|No| J["Continue maintenance HCQ + low-dose CS"]:::action ``` ## Why Each Option Is Correct or Wrong | Option | Assessment | |--------|------------| | **Option 2 (Correct)** | Hydroxychloroquine + low-dose prednisolone + 24-h urine protein quantification is the evidence-based induction regimen for early lupus nephritis with mild proteinuria. Close monitoring allows timely escalation if needed. | | Option 0 | NSAIDs alone are insufficient; active lupus nephritis requires corticosteroids. Delaying corticosteroids risks progression to proliferative disease. | | Option 1 | Pulse methylprednisolone is excessive for mild proteinuria and stable renal function; reserved for Class III–IV nephritis. Immediate renal biopsy is not indicated without failure of standard therapy. | | Option 3 | Azathioprine monotherapy is inadequate; it is used as adjunctive therapy with corticosteroids, not as induction monotherapy. Deferring corticosteroids in active nephritis increases risk of irreversible renal damage. |